

Versameb to Present during World Continence Week 2022

- *Lead therapeutic candidate has the potential to treat Stress Urinary Incontinence*
 - *Raising awareness of the high unmet medical need of patients*

20 June 2022, Basel, Switzerland: Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, is pleased to announce that Chief Executive Officer Klaas Zuideveld and Clinical Advisor Prof. Roger Dmochowski will be presenting Versameb’s lead therapeutic candidate, VMB-100, for the treatment of Stress Urinary Incontinence (SUI) at [World Continence Week](#) (WCW) 20-26 June 2022. WCW is an annual initiative fully endorsed by the European Association of Urology (EAU) and the International Continence Society (ICS) set up by the World Federation of Incontinence and Pelvic Problems (WFIPP) to raise awareness of bladder & bowel issues, chronic pelvic pain and other debilitating conditions which impact the lives of millions of patients worldwide.

During WCW, Versameb will be presenting its proprietary *VERSagile* mRNA technology platform and lead therapeutic candidate VMB-100, a potential treatment for Stress Urinary Incontinence (SUI). VMB-100 has first-and best-in-class potential and has generated promising pre-clinical data showing muscle tissue regeneration and function restoration of the urinary sphincter. Approximately 30% of adult women worldwide suffer from SUI. There is currently no drug treatment approved that restores function and has a long-term effect. *VERSagile* mRNA technology is well suited for the regeneration of muscle tissue and VMB-100 aims to make a difference in this hard-to-treat disease.

For more information and resources on SUI, please see Versameb’s [SUI fact sheet](#).

[World Continence Week](#)

Webinar Session: *Highlighting the need for a therapeutic solution in Stress Urinary Incontinence*

Presenters: *Klaas P. Zuideveld & Prof. Roger Dmochowski, Vanderbilt University Medical Center*

Date & Time: *Friday, 24 June 2022, 15.30pm – 16.30pm CET*

Klaas Zuideveld, Chief Executive Officer of Versameb, said: “World Continence Week raises awareness around the taboo subject of continence related issues. Women are desperately seeking options that have low risk and a long-term lasting effect in improvement or resolution of SUI. Our lead therapeutic candidate is demonstrating a significant acceleration of functional recovery and tissue regeneration to address the high unmet medical need and change the lives of patients suffering from SUI.”

-Ends-

Contact for media enquiries:

Versameb

Klaas Zuideveld, CEO

ir@versameb.com



Optimum Strategic Communications

Mary Clark, Zoe Bolt, Charlotte Hepburn-Scott

Tel: +44 (0)20 3882 9621

versameb@optimumcomms.com

About Versameb

Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb's proprietary technology platform, *VERSagile*, optimizes the application of functional RNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve.

The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. Versameb is working towards a first in-human/proof-of-concept clinical study while advancing its platform. More information on Versameb can be found at www.versameb.com as well as on [LinkedIn](#).